In contrast to neurofilaments and genetic modifiers, SMN protein and SMN-mRNA appear to be promising predictive and pharmacodynamic biomarkers for systemic treatments in both pediatric and adult SMA patients (55). Here, SMN2 is linked to proximal spinal muscular atrophy.